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DNP Practice Inquiry Project Overview
“The impending crisis, which has been foreseen for decades, is now upon us.
The nation needs to act now to prepare the health care workforce to meet the care needs of older
adults.” Institute of Medicine.
Given the rising tide of people over the age of 65, taking multiple medications or

polypharmacy is a becoming more prevalent in older adults. Unfortunately, there are many
negative consequences associated with polypharmacy. Specifically, this burden has been
associated with greater health care costs and an increased risk of adverse drug events, druginteractions, medication non-adherence, reduced functional capacity and multiple geriatric
syndromes including cognitive impairment. Cognitive impairment, seen with both delirium and
dementia, has been associated with polypharmacy. Current medical practice guidelines often
require multiple medications to treat each chronic disease state for optimal clinical benefit.
Cognitive impairment can put a patient at risk for either under- or overtreatment due to their
numerous chronic illnesses requiring treatment.
In Primary Care, the burden of polypharmacy can be daunting, especially when patient
visit times are short and there are other issues to be addressed. There is a lack of an evidencebased, step-by-step protocol to address polypharmacy in Primary Care that can take the
healthcare provider and patient through the medication list together, efficiently. If there was such
an instrument, polypharmacy could be focused on and adverse reactions such as hospitalizations,
falls, and cognitive impairment could be avoided. The purpose of this DNP project is to
investigate the impact of polypharmacy on older adults and what is available in the literature to
address this problem in primary care. Then implement a streamlined Polypharmacy Protocol in
this type of setting to investigate its positive and negative attributes for future use to apply to the
problem of polypharmacy.
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Policy Analysis: Elder Financial Fraud and Polypharmacy
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Abstract
While all types of elder abuse and neglect are serious problems affecting thousands of

vulnerable elders, financial exploitation has especially serious implications for the victims’
economic well-being and quality of life. Older adults living independently may suffer from mild
cognitive impairment or take multiple drugs, known as polypharmacy, causing drug interactions
that could lead to potential mental confusion. These cognitive deficits may frame an older adult
to be taken advantage of unsuspectingly. Financial exploitation may deprive the victims of their
life savings and assets and thus their economic foundation for independence. Current legislation
focuses on identifying scams designed to strip seniors of their assets by helping seniors, their
families, and caregivers identify and avoid fraud schemes. There is also regulations to improve
the complaint system for seniors involved in fraud schemes and enhancing the monitoring of the
types of schemes and number of seniors targeted. The Seniors Fraud Protection Act of 2013 list
of interventions includes: case management for frail, cognitively impaired elders; preventive
educational programs; and ongoing collaboration among adult protective services, financial
institutions, and law enforcement agencies. The purpose of this paper is to appraise current
legislation in regards to financial and material exploitation of the elderly and the role
polypharmacy plays with impairing cognition as a possible factor in this detrimental crime.
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Statement of Issue
Financial or material exploitation is “the illegal or improper use of an elder's funds,

property, or assets.” Examples include but are not limited to cashing checks without
authorization or permission; forging an older person's signature; misusing or stealing an older
person's money or possessions; coercing or deceiving an older person into signing a document
(e.g., contracts or a will); and the improper use of conservatorship, guardianship, or power of
attorney” (Administration on Aging, 1998). In the elderly, an increased number of medications
can have a negative impact on orientation, memory and judgment leading to more cases of
financial and material exploitation. Recreational drugs such as alcohol, as well as over-thecounter (OTC) and prescription medications, may cause a range of cognitive impairments from
confusion to delirium, and may even mimic dementia (Rogers, Wiese, & Rabheru, 2008).
Polypharmacy (defined as use of more than five drugs concurrently), is common among older
adults, and increases the risk of adverse interactions that may interfere with cognition (Rogers et
al., 2008). Age and disease-associated changes in brain neurochemistry combined with
polypharmacy to treat multiple chronic diseases, can predispose an older adult to not recognize
financial or material exploitation (Moore & O’Keeffe, 1999).
Background
Magnitude of issue
A Federal Reserve Survey of Consumer Finances for 2010 found that households with
people 65 and older had approximately one-third of the wealth of the United States
(Administration on Aging, 2010). Elder fraud is becoming more prevalent as the overall
population ages and possibly suffers from cognitive impairment while taking multiple
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medications to control chronic diseases. According to the Administration on Aging (2010), the
older population is defined as those 65 or older, and there will be about 72.1 million Americans
that meet this demographic by 2030, representing 19 %of the population. Nearly one-half (48%)
of the victims of financial/material exploitation were 80 years of age and older, while another
28.7% were between 75 and 79 years of age (Administration on Aging, 2010). Next, elderly
victims between 70 and 74 years of age and those between 65 and 69 accounted for 10.8% and
9.4%, respectively (Administration on Aging, 2010). Victims between 60 and 64 years old
accounted for 3.1% of financial/material exploitation. Friends/neighbors (15%), hospitals
(14.2%), and family members (14%) were the three most frequent reporters of substantiated
financial/material exploitation (Administration on Aging, 2010). Elder fraud costs U.S. seniors
$3 billion a year, according to a report from Federal Trade Commission (Mushnick, 2013).
Psychological researchers suggests that age-related changes in memory, cognition, and
emotion can make elderly Americans more vulnerable to fraud and leading to underreporting of
victimization (Administration on Aging, 1998). Researchers have concluded that approximately
80 percent of elder abuse cases may go unreported (Curtis, 2006). In most cases, the reporting
party is not the victim, but rather a family member, friend, caregiver, or advisor. There are a
variety of reasons that elderly victims do not report abuse, including the following: a) belief that
they are to blame, b) sense of shame or embarrassment, c) emotional or economic dependence on
the abuser, d) fear of separation from home or family, e) fear of the criminal justice system, and
f) lack of knowledge of their rights and alternatives available to them (Curtis, 2006). When
crimes are not reported, victims may not receive supportive services and perpetrators are free to
continue victimizing others (Curtis, 2006).
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A study, published in the Clinical Gerontologist, entitled “Is psychological vulnerability

related to the experience of fraud in older adults?” the authors reviewed financial exploitation of
any kind within the older adult population (Lichtenberg, Stickney, & Paulson, 2013). The study
included 4400 participants and highlighted prospective predictors of reported financial fraud
victimization of older adults including those who are psychologically vulnerable (Lichtenberg et
al., 2013). Those elders, who had the highest level of depression, more medications on their
regimen, and perceived low social-status, were more vulnerable to experience financial fraud
(Lichtenberg et al., 2013).
Financial exploitation is pervasive among all races, social economic status, and gender.
Funds lost from exploitation that could be used to pay for basic needs such as housing, food, and
medical care, effects every demographic. Financial/material exploitation was the third most
frequent type of elder abuse behind neglect and emotional/psychological abuse involving 30.2%
of the victims (Administration on Aging, 2010). Female elders were victims of financial/material
exploitation somewhat more than their proportion of the elder population (63% vs. 57.6%), while
male elders were victims of exploitation 37% of the time. The proportion of white victims of
financial/material exploitation was 83% (Administration on Aging, 1998). Black elders
comprised 15.4% of abuse victims of this type of elder maltreatment (Administration on Aging,
2010).
Historical health policy overview
It is only in recent decades that elder mistreatment as a social policy issue has moved to
the forefront of health care and social services in the United States. The passage of Medicare,
Medicaid, and the Older Americans Act legislation in the 1960s was a shift toward increased
awareness to welfare issues impacting the elderly (Falk, Baigis, & Kopac, 2012). In 1974, Title
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XX of the Social Security Act authorized the support of protective services to adults 18 years of
age and older at all income levels who were suffering abuse, neglect, or exploitation. This
legislation stimulated the creation of Adult Protective Services at the state level.
In 1987, the Administration on Aging, as part of the Department of Health and Human
Services, established the Prevention of Elder Abuse, Neglect, and Exploitation program.
Through the program, the Administration on Aging provides federal leadership in strengthening
elder justice strategic planning and direction for programs, activities, and research related to
elder abuse awareness and prevention. This program trains law enforcement officers, health care
providers, and other professionals on how to recognize and respond to elder abuse; supports
outreach and education campaigns to increase public awareness of elder abuse and how to
prevent it; and supports the efforts of state and local elder abuse prevention coalitions and
multidisciplinary teams. The situation improved in 2003 when Senator John Breaux introduced
the Elder Justice Act in the U.S. Senate to highlight the human rights issue of freedom from
abuse and exploitation (Falk, et al., 2012).
In March of 2010 the Elder Justice Act was passed as a law to authorize the expenditure
of the federal funds to implement the law and provide benefits to elders nationwide. It is
regarded as the most comprehensive bill ever passed to combat elder abuse, neglect, and
exploitation (Falk, et al., 2012). The Elder Justice Act authorizes $770 million in spending in the
years 2010-2014. Of this total, approximately $500 million has been earmarked for Adult
Protective Services (APS) (Falk, et al., 2012). In May 2013, new legislation that assist the Elder
Justice Act in combating elder financial fraud, is a bill entitled The Senior Fraud Prevention Act.
It was introduced in the United States House of Representatives and Senate to focus attention on
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monitoring the market for mail, television, Internet, and telemarketing fraud including recorded
message telephone calls (robocalls) targeting seniors.
The Senior Fraud Prevention Act of 2013 directs the Federal Trade Commission (FTC) to
establish an office within the Bureau of Consumer Protection to advise the FTC on the
prevention of fraud targeting seniors and to assist the FTC in monitoring the market for mail,
television, Internet, and telemarketing fraud including recorded message telephone calls
(robocalls) targeting seniors (House Bill 1953 Summary & Status, 2013). This will help protect
seniors from fraud schemes by strengthening the complaint system to ensure complaints of fraud
are handled quickly by the appropriate law enforcement agencies. The bill would also require the
FTC, to coordinate with other agencies to monitor the market for fraud schemes targeting
seniors. In addition, the bill would require the FTC to distribute information materials to seniors,
their families, and their caregivers that explains the process for contacting law enforcement
authorities in the event that a senior is targeted in a fraud scheme.
Conceptual Framework
In John Kingdon’s Agendas, Alternatives, and Public Policies (2011) he states that there
are three stages in the policymaking process: initiation, formulation and implementation. He
devised a model that comprises three “streams” that flow individually but are important in the
policymaking process. When two or three streams meet, a policy or bill will move forward. The
three streams are: The recognition of something as a problem (problem stream); the
identification of possible solutions (proposal stream); the necessary opportunities at the time of
the item being added to public policy (political stream).
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The problem stream involves persuading policy makers to pay attention to one problem

over other problems. This is also known as agenda setting. Policy proposals will rise to the top of
the agenda when the associated problem is recognized as important. This depends on how it is
framed or brought to policy maker’s attention. The proposal stream is the process by which
policy proposals are generated, debated, revised, and put forth for consideration. For the policy
proposal to be successful it must be perceived as feasible, compatible with policymaker’s values,
reasonable in cost, and appealing to the public (Kingdon, 2011). The political stream refers to
the factors that influence agendas. This includes “swings of national mood, vagaries of public
opinion, election results, changes of administration, shirts in partisan or ideological distributions
in Congress, and interest group pressure campaigns” (p.87).
The Senior Fraud Prevention Act of 2013 aligns with Kingdon’s Three Streams
framework. There was recognition of the rising incidences of elder exploitation by the public but
also by policy makers, thrusting this issue to the top of the agenda or problem stream. A
bipartisan proposal was created, revised, and introduced by sponsors in both the Senate and
House of Representatives. This indicates that the Senior Fraud Prevention Act flows into the
proposal stream since it is feasible, compatible with the all of the policymaker’s values,
reasonable in cost, and appealing to the public (Kingdon, 2011). The factors that influence
agendas of the political stream for this policy include interest groups campaigns to raise
awareness of elder exploitation and fraud, public opinion on the topic, and the ideology of the
congress men and women who put forth the Senior Fraud Prevention Act. Supporting The Senior
Fraud Prevention Act of 2013 with Kingdon’s Three Streams framework demonstrates that there
is a high probability of this policy moving forward through the political process and becoming
law.
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Discussion
The Senior Fraud Prevention Act of 2013 is an important policy and strategy to address

the detrimental effects exploitation has on the elderly. Exploitation isolates the victim and
promotes a sense of helplessness, hopelessness, and/or powerlessness. Early intervention and
reporting can prevent devastating emotional and financial losses for older persons who have
worked their entire lives to become financially independent. This policy will give seniors and
their families the tools they need to avoid scams before they happen, and will also help make
sure that when a complaint is filed, it gets into the right hands so it can be addressed swiftly and
effectively. According to US Senators Amy Klobuchar and Susan Collins who introduced this
policy, the bill would help protect seniors from fraud by establishing an advisory office within
the Bureau of Consumer Protection (Klobuchar, 2013). The Bureau of Consumer Protection
office would be responsible for increasing oversight, consumer education, and establishing a
complaint tracking system focused on scams that target our seniors (Klobuchar, 2013).
In the article entitled Financial exploitation of older persons: Policy issues and
recommendations for addressing them (2004), the authors address several policy issues and
make recommendations for an effective public policy approach to combatting financial
exploitation of elders. These recommendations are considered to be part of the plan to improve
social service, legal and criminal justice systems’ response to victims of financial exploitation
(Rabiner, Brown, & O’Keeffe, 2004). The policy options include: understand risk factors for
victimization; understand perpetrators of financial exploitation; accurate reporting of incidence
and prevalence data; understand the full impact of financial exploitation; determine effectiveness
of money management programs; key elements of successful prosecution of financial crimes;
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reduce the misuse of powers of attorney; effectiveness of financial exploitation prevention
messages; improve the process for appointing and monitoring guardians; establish restitution
programs; and multidisciplinary training on financial exploitation (Rabiner, et al., 2004).
The Senior Fraud Prevention Act 2013 is focusing on accurate reporting of the incidence
of fraud in an effort to disseminate information to seniors, their families, and caregivers, on the
most common fraud schemes. This information will go directly to the FTC where complaints
will be directed to the Federal Bureau of Investigation, state attorney general’s office, and law
enforcement agencies for further investigation. This will allow for evaluation of effectiveness of
financial exploitation prevention messages; help better understand risk factors for victimization;
allow for accurate reporting of incidence and prevalence data; improve the process for
appointing and monitoring guardians; and understand the full impact of financial exploitation.
Taking into consideration the recommendations outlined by Rabiner, Brown and
O’Keeffe (2004), the following need to be implemented for legislation to be effective: better
identification of perpetrators of financial exploitation; reduce the misuse of powers of attorney;
improve the process for appointing and monitoring guardians; establish restitution programs;
establish key elements of successful prosecution of financial crimes and multidisciplinary
training on financial exploitation. Several national groups such as the National Council on Aging
and AARP (American Association of Retired Persons) have published news releases and
information on how to combat elder financial fraud. These types of news releases disseminate
information to seniors, their caregivers, and families, on how to protect their loved ones from
financial exploitation.
Possible implementation issues with the Senior Fraud Prevention Act of 2013 include its
vast outreach issues. Since the older adult population is continuously increasing in the United
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States, discerning information about the latest financial fraud scams and victimization reports is
going to take not only federal leadership but state and local agency leadership as well. Once this
public policy is implemented, it must be reconciled with already existing policies regarding the
issue of elder exploitation as highlighted in the historical context of this paper. Once this policy
is approved into law, if it is dependent on a certain level of funding or participation, this will
ultimately be the deciding factor in how far this policy will go towards battling the issue of
financial exploitation. Also, for the Senior Fraud Prevention Act of 2013 to succeed it must be
supported publicly by local agencies that are a part of this fight to help seniors avoid
exploitation.
Conclusion
Due to age and disease-related changes in the brain and how the brain manages
medications, can cause drug interactions leading to potential mental confusion. Polypharmacy is
common among older adults and increases the risk of adverse interactions that may interfere with
cognition. These cognitive deficits may cause an older adult to be taken advantage of
unsuspectingly. Financial exploitation is one type of elder abuse that affects thousands of
vulnerable elders that can deprive the victims of their life savings and assets and thus their
economic foundation for independence. The Seniors Fraud Protection Act of 2013 is current
legislation that focuses on fighting scams designed to strip seniors of their assets and prevent
devastating emotional and financial losses for older persons who have worked their entire lives
to become financially independent. This policy will give seniors and their families the tools they
need to avoid scams and allow for proper follow-up when a complaint is filed, so it can be
addressed effectively to prevent further exploitation to older adults.
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Abstract

Purpose: The purpose of this literature review is to critically evaluate published protocols on
polypharmacy in adults ages 65 and older that are currently used in primary care settings that
potentially lead to fewer adverse drug events.
Methods: A review of OVID, CINAHL, EBSCO, Cochrane Library, Medline, and PubMed
databases was completed using the following key words: protocol, guideline, geriatrics, elderly, older
adult, polypharmacy, and primary care. Inclusion criteria were: articles in medical, nursing, and
pharmacology journals with an intervention, protocol, or guideline addressing polypharmacy that
lead to fewer adverse drug events. Qualitative and quantitative studies were included. Exclusion
criteria were: publications prior to the year 1992.
Results: A gap exists in the literature. No standardized protocol for addressing polypharmacy in the
primary care setting was found. Mnemonics, algorithms, clinical practice guidelines, and clinical
strategies for addressing polypharmacy in a variety of healthcare settings were interspersed
throughout the literature. Several screening instruments for use in primary care to assess potentially
inappropriate prescription of medications in the elderly, such as the Beers Criteria and the STOPP
screening tool, were identified as well. However, these instruments were not included in a
standardized protocol to manage polypharmacy in primary care.
Conclusion: Polypharmacy in older adults is a critical problem that may result in adverse drug
events such as falls, hospitalizations, and increased expenditures for both the patient and the
healthcare system. No standardized protocol to address polypharmacy was located in the literature.
Given the growing population of elderly in this country and the high number of medications they
consume, it is critical to focus on the utilization of a protocol to address polypharmacy in primary
care and evaluate its effects on patient outcomes.
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Introduction
There is a lack of consensus on the definition of polypharmacy among healthcare

professionals. The two most common definitions are the use of potentially inappropriate drugs
and the concurrent use of five or more medications including prescription and over-the-counter
drugs (Bushardt, Massey, Simpson, Ariail, & Simpson, 2008). Polypharmacy is distinct from
polymedicine, which is the use of many medications to treat multiple health problems (Michoki,
2001). The elderly, defined as those aged 65 years and older, have on average six co-morbid
chronic conditions that require multidrug therapy to cure, slow progression, or reduce the
symptoms of disease (Bushardt et al., 2008). Evidence based guidelines recommend several
drugs in the treatment or prevention of a single medical condition such as in the case of diabetes
mellitus or heart failure (Viktil, Blix, & Reikvam, 2008). The elderly tend to consume more
over-the-counter (OTC) products than any other demographic group and account for 30% of
OTC drug use in the U.S. (Francis, Barnett, & Denham, 2005; National Council on Patient
Information and Education, 2010). Consequently, elderly patients likely take several
medications, both prescription and OTC, concurrently. There is a multiplicative relationship
between the number of medications and the number of drug-related problems that occur; with
each additional medication, the number of adverse reactions rises exponentially (Zurakowski,
2009).
The U.S. Census Bureau projects that by the year 2020 there will be 55 million people
over the age of 65; this group will represent 20% of the U.S population and consume 50% of
healthcare costs (Vincent & Velkoff, 2010). Prescriptions for the elderly, account for 25% to
40% of all prescriptions written in the United States (Ferrario, 2008). Studies have found that a
larger number of medications used by a patient leads to an increased risk of adverse drug
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reactions and events, poorer patient compliance, and a larger economic burden (Bregnhoj,
Thirstrup, Kristensen, Bjerrum, & Sonne, 2009). Other consequences of polypharmacy include:
drug-drug interactions leading to hospitalization; change in functional status; cognitive
impairment; urinary incontinence; and change in nutrition status (Maher, Hanlon, & Hajjar,
2014). Adverse drug reactions and other medication related problems such as falls and
hospitalizations are associated with significant mortality; over 100,000 deaths occur annually in
the U.S. due to medications at a cost of $85 billion each year (Bilyeu, Gumm, Fitzgerald, Fox, &
Selig, 2011). The relatively high rates of medication use by elderly in combination with the
physiologic changes associated with aging such as decreased renal output, hepatic function,
serum albumin levels, and total body water and lean body mass increase the prevalence of
medication associated mortality (Bushardt et al., 2008).
Purpose
The use of medications is essential for treating chronic health conditions and maintaining
quality of life. The use of potentially inappropriate medications is a known risk factor for adverse
drug reactions in the elderly along with polypharmacy and inconsistent adherence to the drug
regimen (Bilyeu et al., 2011). Inappropriate prescribing is an umbrella term for uncontrolled
polypharmacy, under-prescribing, the prescription of medications that have more potential risk
than benefit, and poor prescribing practices by healthcare providers that lead to adverse drug
events (Penge & Crome, 2013). When a medication is used incorrectly or prescribed
inappropriately, it can cause physical or psychological harm to a patient (Lam & Cheung, 2012).
This can lead to increased healthcare utilization and expenditure. Appropriate prescribing by a
healthcare provider is the fundamental first step in the proper use of a medication (Lam &
Cheung, 2012). Evidence-based prescribing and following guideline directed therapy allows the
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prescriber to be more confident and avoid adverse outcomes. However, if the medication has the
potential for more risk than benefit to a patient or a safer, more effective alternative is available,
this medication is considered inappropriately prescribed (Lam & Cheung, 2012).
Improving prescribing practices and decreasing adverse drug events in the elderly would
have significant health and financial benefits. To produce these results, improved medication
reconciliation and prescribing by the healthcare provider must be initiated to reduce the number
of potentially inappropriate medications prescribed for elderly patients. The purpose of this
literature review is to critically evaluate evidence based protocols on polypharmacy in elderly
patients in the primary care.
Methods
Using the key words “protocol”, “guideline”, “geriatrics”, “elderly”, “older adult”,
“polypharmacy”, and “primary care”, the OVID, CINAHL, EBSCO, Cochrane Library, Medline,
and PubMed databases were searched. Articles published in the 15 year period from 1998
through 2013 was chosen for review of the most current state of the evidence. One article
published in 1992 was included because it contained a well-documented and applied screening
instrument for practice. Inclusion criteria were: articles in medical, nursing, and pharmacology
journals with a protocol or clinical practice guideline or other clinical strategy for polypharmacy
that led to fewer adverse drug events as the outcome variable. A clinical practice guideline is
designed to support decision-making processes in patient care with content based on a systematic
review of the clinical evidence. A protocol is viewed as more specific than a guideline, as it
provides a comprehensive set of criteria outlining the management steps for a single clinical
condition (Field & Lohr, 1992). Qualitative and quantitative studies were included. Sixteen
articles met the criteria for inclusion in this review.
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The articles were reviewed using the categories of: (a) Author (Date); (b) Type of Study;

(c) Sample; (d) Purpose; (e) Findings; (f) Implications; (g) Evidence Level; and (h) Strength of
Evidence. They were further grouped into subheadings of: Clinical Strategies, Algorithms,
Acronyms, Guidelines, and Screening Instruments. The Hierarchy of Evidence Rating System
used was the Strength of Recommendation Taxonomy (SORT) (Ebell et al., 2004). This system
rates the evidence from Levels A to C, with Level A being consistent, good-quality patientoriented evidence. Level B is inconsistent or limited-quality patient-oriented evidence, and Level
C is consensus, disease-oriented evidence. The SORT system also is used to assess the quality of
evidence of the studies where Level I is the highest and Level III is the lowest.
Results
The search yielded 16 articles that describe a broad range of approaches to address
polypharmacy in the elderly including: screening instruments to reduce the prescription of
inappropriate medications by healthcare professionals, expert clinical opinion strategies or
recommendations, an algorithm for reducing or discontinuing medications, mnemonics for use
by clinicians while reconciling a medication list, and clinical practice guidelines. Key findings
from the articles are summarized in the following sections and in the Appendix.
Screening Instruments
Screening instruments in the literature can be applied in clinical practice to allow for
closer monitoring of drug use, application of interventions to decrease adverse drug events in the
elderly, and better patient outcomes. Four screening instruments were located in the literature:
the American Geriatrics Society (2012) Beers Criteria; the Screening Tool of Older Person’s
Prescriptions (STOPP) (Gallagher, Ryan, Byrne, & O’Mahony, 2008); the Medication
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Appropriateness Index (MAI) (Hanlon, Samsa, Weinberger, Uttech, Lewis, & Feussner. 1992);
and the Hyperpharmacotherpay Assessment Tool (HAT) (Bushardt at al., 2008).
The American Geriatrics Society (2012) updated the 2001 Beers Criteria to: improve the
selection of prescription drugs by clinicians and patients; evaluate patterns of drug use within
populations; educate clinicians and patients on proper drug usage; and evaluate health-outcomes,
quality of care, cost, and utilization data. This Systematic Review (Level I Evidence, SORT A)
encompasses 53 medications or medication classes divided into three categories: potentially
inappropriate medications and classes to avoid in older adults; potentially inappropriate
medications and classes to avoid in older adults with certain diseases and syndromes that the
drugs listed can exacerbate; and medications to be used with caution in older adults. Limitations
of the Beer’s Criteria are that it does not address potentially inappropriate medications (PIMs)
commonly prescribed to older adults including drug-drug interactions, dosing of drugs in renal
impairment, and therapeutic duplication (Penge & Crome, 2013). It also does not provided a list
of alternative medications, requiring the provider to have patient specific judgment. According to
Penge and Crome (2013), little evidence supports the use of the Beer’s Criteria in terms of
clinical outcomes and lack of significant associations between PIMs and adverse drug reactions.
Gallagher et al. (2008) developed the Screening Tool of Older Person’s Prescriptions
(STOPP) to incorporate potentially inappropriate medication use in the elderly, including drugdrug interactions and duplicate class prescribing, using a Delphi consensus technique with an 18member expert panel (Level I evidence, SORT A). Sixty-five medications were identified and
agreed upon by the expert panel and then recorded under physiologic systems (cardiovascular,
central nervous, gastrointestinal, respiratory, musculoskeletal, urogenital, and endocrine).
Gallagher and O’Mahony (2008) conducted a cross-sectional study with 715 elderly patients
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with consecutive acute hospital admissions to compare the performance of STOPP to the Beers
Criteria in detecting potentially inappropriate medicines and adverse drug events. STOPP
identified PIMs in 35% of patients compared with only 25% using the Beers Criteria. Also, the
STOPP criteria PIMs, unlike Beers criteria PIMs, are significantly associated with avoidable
adverse drug events (ADEs) in older people with acute illness that cause or contribute to urgent
hospitalization (Hamilton, Gallagher, & O’Mahony, 2009). Previous studies had not
demonstrated a consistent association between PIMs in older patients as defined by the Beers
criteria and avoidable ADEs.
Hanlon et al. (1992) developed the Medication Appropriateness Index (MAI), a 10component assessment tool, to assist physicians and pharmacists in assessing the appropriateness
of a medications in elderly patients (Level I evidence, SORT A). The overall inter-rater
agreement for the MAI was .88 and for medication inappropriateness was .95; the overall kappa
was .83. The components include efficacy, drug dosage, interactions, cost, and duplications and
provide a reliable method to assess drug therapy appropriateness. The MAI is not drug specific
like the Beers or the STOPP criteria. The MAI requires clinical judgment on the part of the
provider and incorporates explicit instructions to help standardize the process of medication
reconciliation with a good inter-rater reliability (Penge & Crome, 2013).
The Hyperpharmacotherpay Assessment Tool (HAT) was adapted from Bergman’s
Medication Management Guideline (2006) for residents in long-term care (Level III evidence,
SORT C). Bushardt et al. (2008) designed the HAT to meet six goals to avoid polypharmacy:
monitor number of medications; decrease inappropriate drug use; decrease inappropriate
pharmacology; optimize dosing regimen; organize sources of medication; and educate the
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patient. Additional research is needed to refine this instrument since it has not been validated in
clinical practice.
Clinical Strategies
Clinical strategies and recommendations are available to enhance clinician and patient
awareness of polypharmacy, to reduce its risks and drug costs. Three clinical strategies were
identified in this review of the literature. They include a pharmacist directed education
intervention program (Zarowitz, B.J., Stebelsky, L.A., Muma, B.K., Romain, T.M, & Peterson,
E.L., 2005), nine key questions to address polypharmacy in the elderly (Bushardt, R. L. & Jones,
K.W., 2005), and safe prescribing suggestions to avoid the pitfalls of polypharmacy
(Zurakowski, T., 2009).
In a longitudinal, time series cohort study with two interventions separated by one year,
five categories of high-risk drug combinations were identified to reduce polypharmacy in
members of a managed care plan (Level II evidence, SORT A). Clinical pharmacists performed
drug therapy reviews and provided education to physicians and patients about drug safety and
ways to correct problems with polypharmacy (Zarowitz et al., 2005). This intervention reduced
drug costs and number of prescriptions in patients at high risk for adverse drug events due to
polypharmacy. The overall rate of polypharmacy events decreased from 29.01 to 9.43/1,000
patients (a 67.5% reduction) after the first intervention. After the second intervention, the overall
rate decreased from 27.99 to 17.07/1,000 (a 39% reduction). The use of pharmacists to provide
clinical information, decision support, patient self-management, and care delivery redesign
solved some of the problems resulting from polypharmacy (Zarowtiz et al., 2005).
Bushardt and Jones (2005) in an expert opinion article, outlined nine key questions to ask
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during a primary care visit to address polypharmacy in the elderly and help patients avoid
medication-related problems (Level III evidence, SORT C).
Table 1. Nine key questions to address polypharmacy in the elderly
1) Is each medication necessary?
2) Is the drug contraindicated in the elderly?
3) Are there duplicate medications?
4) Is the patient taking the lowest effective dosage?
5) Is the medication intended to treat the side effect of another medication?
6) Can the drug regimen be simplified?
7) Are there potential drug interactions?
8) Is the patient adherent?
9) Is the patient taking an OTC medication, herbal product, or another person’s medication?

To address the harm of polypharmacy in the elderly, Zurakowski (2009) provided a
framework based on expert opinion for safe prescribing in the elderly to avoid medication related
problems (Level III evidence, SORT C). The recommendations included: review the medication
list at every visit; evaluate the patient’s adherence; consider every new symptom or complaint as
a possible drug-related problem and investigate it; use the Beers Criteria (2012) as a filter when
considering a new medication and identify potentially inappropriate medications used in the
elderly; ensure that each medication on the list has a clear indication; ask about the use of OTC
products; “start low and go slow” when prescribing; and consult another healthcare professional
such as pharmacist on a regular basis.
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Algorithms are a streamlined method to approach a problem in the clinical setting. They
have the potential to be an efficient and safe technique to reduce the adverse effects of multiple
medications in elderly patients. Only one algorithm was found in the literature: the Good
Palliative-Geriatric Practice algorithm (Garfinkel & Mangin, 2010).
Garfinkel and Mangin (2010) tested the feasibility of the Good Palliative-Geriatric
Practice algorithm in a cohort study to improve drug therapy in community-dwelling elderly
patients (Level II evidence, SORT A). This algorithm takes the healthcare provider through a
series of yes and no stages to either stop a drug, shift to another drug, continue with the same
drug, or reduce the dose of the current drug. Of the 70 elderly patients in the study, successful
discontinuation of medications not immediately essential for life was achieved for 81% with no
significant adverse events or deaths attributable to discontinuation. Also, 88% of patients
reported global improvement in health.
Mnemonics
Several publications listed mnemonics as a pattern of letters or associations to assist
healthcare providers in remembering strategies to reduce polypharmacy in the elderly. Four
mnemonics were located in the literature: SAIL (Lee, 1998), AMROR (Haque, 2009), TIDE
(Shah & Hajjar, 2012), and MASTER (Hoskins, 2011). The four mnemonics are listed in Table 2
but not in the Appendix since they are a technique that aids information retention and not studied
extensively.
Table 2. Mnemonics to reduce polypharmacy in the elderly
SAIL (1998)
S simple; prescribing drugs that can be taken once a day or adding a combination pill when a

25"

"

"
"
"
"
"

"
"
"

"
"

"
"

"
second pill must be added keeps a patient’s drug regimen uncomplicated.

A adverse; the clinician must have knowledge of the adverse effects of all the drugs a patient is
taking to avoid medication interactions
I indication; there must be a clear indication for each drug a patient is taking with a desired
therapeutic goal in mind
L is for list; the patient’s medication list must be accurate including OTC products, herbs, and
alternative medications and correspond to their medical diagnoses.
ARMOR (2009)
A assess the individual for the total number of medications and for certain groups of medications
that have potential for adverse outcomes in the older adult such as beta blockers,
antipsychotics, and antidepressants
R review for possible drug-drug, drug-disease, and drug-body interactions
M minimize nonessential medications that lack a clear indication; the risks outweigh the benefits
that could have a negative outcome on primary functions such as appetite, bladder/bowel,
activity, and mood
O optimize by addressing duplication of drugs, adjustment of drugs for renal and hepatic
function, reducing oral hypoglycemics, and monitoring anticoagulants and seizure medications
carefully
R reassessment of the patient’s vital signs, cognitive status, function, and medication compliance
TIDE (2012)
T time; allow sufficient time to address and discuss medication issues during each encounter
I individualize; apply pharmacokinetic and pharmacodynamics principles to regimens by
adjusting doses for renal and hepatic impairment and starting medications at the lowest
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effective dose

D drug interactions; consider potential drug-drug and drug-disease interactions
E educate; educate the patient and caregiver about non-pharmacological and pharmacologic
treatments along with side effects and monitoring parameters
MASTER (2011)
M minimize drugs used
A alternatives that should always be considered, especially non-drug therapies
S start low and go slow
T titrate therapy, adjusting dose based on individual response
E educate the patient and family member with clear, written instructions
R review regularly
Clinical Practice Guidelines and Quality Indicators
Clinical practice guidelines are an evidence-based strategy to address a clinical issue such
as polypharmacy. The aim of a guideline is to direct decisions and criteria regarding diagnosis,
management, and treatment in specific areas of healthcare. Two guidelines met inclusion criteria
for this review of the literature: Assessing Care of Vulnerable Elders (Wenger, Roth, & Shekelle,
2007) and Improving Medication Management for Older Adult Clients Residing in Long-term
Care Facilities (Bergman, 2013).
Assessing Care of Vulnerable Elders (Wenger et al., 2007) is a set of evidence-based
quality indicators designed to measure the quality of care of vulnerable adults in the United
States (Level I evidence, SORT A). There are 26 conditions described to identify areas of care in
need of improvement. This includes medications to avoid in the elderly along with domains of
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care including screening and prevention, diagnosis and treatment, and follow-up. The quality
indicators are not considered the same as practice guidelines. Rather they set a standard that if
not met can identify poor-quality care and are processes of care that are amenable to direct action
by providers. Practice guidelines, in contrast, strive to define optimal care in the context of
complex medical decision-making. According to Penge and Crome (2013), the disadvantage of
this quality indicators project was the lack of evidence of its validity in practice.
Improving Medication Management for Older Adult Clients Residing in Long-term Care
Facilities (Bergman, 2013) is a guideline to maintain function, decrease polypharmacy, avert
adverse drug reactions, and avoiding inappropriate prescribing by healthcare providers (Level I
evidence, SORT A). The guideline identified individuals at risk for problems with medications
as those who: self-treat, lack coordinated care, were recently discharged from the hospital, have
impaired cognitive status, and were on complicated medication regimens. The goal is to provide
long-term care residents with periodic reviews by both a clinician and a pharmacist to review
medications for congruency with diagnoses, remove duplicate medications, assess renal function,
and remove high-risk medications from the list when compared to the Beers Criteria (2012).
Discussion
The Beers Criteria, STOPP instrument, and MAI were developed and studied in clinical
practice to reduce adverse drug events often found with the concurrent use of medications.
Inappropriate prescribing can be detected using explicit (criterion-based) or implicit (judgmentbased) prescribing indicators (Hamilton, et al, 2009). The Beers Criteria (2012) and STOPP
(2008) are explicit or readily observable instruments that must be updated regularly to support
new drugs on the market and evolving clinical practice. One of the most consistent findings is
that the use of Non-steroidal Anti-inflammatory Drugs (NSAIDs) in the elderly is high-risk,
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showing up on both “drugs-to-avoid” lists as well as drug-disease interactions with heart failure,
chronic renal failure, and peptic ulcer disease. Also, both the Beers and STOPP criteria include
tricyclic antidepressants as a class of drugs that can exacerbate a number of conditions including
falls and cognitive impairment. The MAI (1992) is an implicit tool that is predominantly used as
a research tool and requires clinical expertise to apply some of the criteria, resulting in variable
inter-rater reliability (Hamilton, et al., 2009). However, each one of these screening instruments
provides valuable evidence-based information about inappropriate medications in the elderly.
The standards outlined in these instruments need to be assimilated into a step-by-step
management protocol for a clinical condition such as polypharmacy.
A balance is required between over- and under-prescribing medications to elderly
patients as outlined in each of the clinical strategies described in this literature review. Essential
to avoiding polypharmacy and adverse drug events is to continual reappraisal of the patient’s
medication regimen and their current clinical status, matching the medication regimen to the
patient’s condition and goals of care, and weighing the potential risks/benefits of each
medication. However, the clinical strategies lack a standardized approach for the healthcare
provider to guide the tailoring of medication regimens to avoid polypharmacy.
Mnemonics and other memory aids can be helpful to busy healthcare providers in their
daily work when trying to recall information that requires memorization. The mnemonics
described above can assist in remembering the most important parameters when assessing a
patient's drug therapy. The key factors in the use of mnemonics in medication selection
emphasize that prescribers consider all possible pharmacotherapeutic alternatives and remind
them to address issues such as contraindications and precautions. Combining each step of the
mnemonic to include or exclude medications based on individual patient factors allows the
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healthcare provider to arrive at the most suitable medication for the patient and avoid
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"

polypharmacy.
The movement towards evidence-based healthcare has generated the development of
clinical practice guidelines and care indicators to address quality, consistency, and costs.
Guidelines based on standardized practice are capable of supporting improvements in quality and
consistency in healthcare and reduce inappropriate variation in practice (Field & Lohr, 1992).
The drawback to clinical practice guidelines to address polypharmacy is that they do not account
for patients having several medical diagnoses that require multiple medications. The goal of a
healthcare provider reviewing a patient’s medication list is to try and avoid adverse drug events
and drug interactions, but also meet the targets set out by the clinical practice guidelines.
However, the guideline may not take into consideration each patient’s unique set of health
priorities when addressing polypharmacy.
Conclusion
There is a need for a simple, time-efficient screening protocol that can be used routinely
to guide prescribing practice and reduce the rate of adverse drug events in elderly patients in
primary care settings. Protocols are designed in the healthcare system as a standardized way of
performing a task that is repeatable and reproducible. The goals of protocols are to produce
similar results, provide a consistent presentation of data and confidence in results, allow for
efficient auditing procedures, and possibly prevents errors.
To address polypharmacy in primary care, such a protocol should be sensitive, specific,
include commonly encountered adverse drug events, translate into positive clinical outcomes,
and have good inter-rater reliability (Hamilton et al, 2009). This protocol should encompass the
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recommendations highlighted in the articles reviewed in this manuscript. The strategies that are
important to incorporate in the protocol are: (1) inquiring about the use of over-the-counter
products; (2) whether or not the patient sees specialist(s) and/or has been recently discharged
from the hospital; (3) if a medication has been recently added to the regimen to treat the side
effect of another medication (the prescribing cascade); (4) are there any duplications of
medications on the list; (5) is the patient consuming any high risk medications as identified by
the American Geriatrics Society; (6) does each drug in the regimen have a clear indication; (7)
does the patient exhibit any physiologic changes associated with aging that could potentially
cause an adverse reaction; (8) and is the patient taking the lowest therapeutic dose of each
medication. The development and use of a standardized protocol to address polypharmacy in the
elderly population may lead to fewer adverse drug related events such as falls and
hospitalizations, thus improving quality and reducing healthcare costs. "
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Table 3. Articles Reviewed in Order as Presented in the Text
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prescribing habits.

Bushardt & Jones,
(2005)

Expert opinion

N/A

Provide a systematic

See text (Table 1)

To reduce

approach to assess and

for the nine key

manage polypharmacy

questions

in the primary care visit

Level III

C, consensus,

Strengths:

polypharmacy and

disease-

Assessment

help patients avoid

oriented

system for the

medication-related

evidence,

primary care visit

problems.

usual practice

based on various

or expert

definitions of

opinion

polypharmacy;
streamlined effort
to quickly assess
medication lists of
patients and ask
important
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questions
regarding
medication use
and adherence to
avoid adverse
drug reactions.
Weaknesses: Not
tested or data
available to
determine if the
nine questions
have improved
outcomes in the
primary care
setting; does not
list or advise the
provider to
follow-up if
adjustments made
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to patient’s
regimen.

Zurakowski, (2009)

Expert opinion

N/A

Provide safe prescribing

Recommendations: To reduce

tips for older adults for

review the

healthcare providers to

medication list at

weigh the risks and
benefits of a medication

every visit;
evaluate the
patient’s
adherence;
consider every
new symptom or

Level III

C, consensus,

Strengths:

polypharmacy and

disease-

Resource for

help patients avoid

oriented

providers that

medication-related

evidence,

highlights safe

problems

usual practice

prescribing tips

or expert

for older adults.

opinion

Weaknesses: Not
tested or data
available for
improved

complaint as a

outcomes in the

possible drug-

primary care

related problem

setting; only

and investigate it;

refers to the Beers

use the Beers

Criteria when

Criteria (2012) as
a filter when
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considering a new

medication list,

medication and

does not refer to

identify potentially

other screening

inappropriate
medications used
in the elderly;
ensure that each
medication on the
list has a clear
indication; ask
about the use of
OTC products;
“start low and go
slow” when
prescribing; and
consult another
healthcare
professional such
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as pharmacist on a
regular basis.

Algorithm
Author (Date)

Garfinkel & Mangin,
(2010)

Type

Cohort study

Sample

Purpose

Findings

SORT
Strength of
Evidence
Grade
A, based on

N=70

Use of the Good

The algorithm

It is feasible to

Strengths:

community

Palliative-Geriatric

recommended

decrease

consistent and

Evidence based

dwelling

Practice algorithm for

discontinuation of

medication burden

good-quality

developed

older adults

drug discontinuation

311 medications in

with the Good-

patient

algorithm that

has been effective in

64 patients (58% of

Palliative Geriatric

oriented

flows easily

nursing home setting.

drugs). 81%

Practice

evidence

through a series of

Will test feasibility in

successful

algorithm. Clearly

yes or no

community dwelling

discontinuation was

outpatient

questions and

older adults recording

achieved with 2%

medication use

when to stop or
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rate of discontinuation,

restarted because of

among older

continue a

morbidity, mortality,

reoccurrence of

adults is a case

medication; use of

and changes in health

disease. No

where “less is

algorithm

status.

significant events or

more.”

improved the

deaths were

overall wellbeing

attributed to

of the patients

discontinuation and

participating in

88% reported global

the study.

improvement in

Weaknesses: To

health.

date, only tested
on patients in a
long-term care
setting and in
community
dwelling
palliative care
patients;
challenging to
apply to
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medication
reviews with
older adults who
have multiple
comorbidities that
require multiple
medications.

Clinical Practice
Guidelines or Quality
Indicators
Author (Date)

Type

Sample

Purpose

Findings

SORT
Strength of
Evidence
Grade
A, based on

Wenger, Roth, &

Evidence-based

N/A

Provide a measurement

Twenty-six

In regards to

Strengths:

Shekelle, (2007)

quality

set to evaluate the care

conditions described

polypharmacy, the

consistent and

Developed using

indicator

provided to vulnerable

using evidence-

panel of experts

good-quality

high-quality

guideline

older persons at the

based quality

said to avoid:

patient

evidence to form

level of the health

indicators to identify

drugs with strong

oriented

processes for

system, health plan or

areas of care in need

anti-cholinergic

evidence

community-

medical group. The

of improvement to

properties; skeletal

dwelling elders at

quality indicators are

form the basis of

muscle relaxants;

risk for functional

linked to scientific

interventions to

and high dose

decline rather
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benzodiazepines.

than outcomes;

healthcare providers

Along with

the indicators

can enhance their

recommending

cover the

practice.

periodic drug

common geriatric

regimen review

syndromes; and

and noting clear

the quality

indications for

indicators take

each drug on the

into account the

list.

patient’s
preferences.
Weaknesses:
Feasibility in
primary care
practice due to the
indicators being
designed to
measure care at
the level of the
health system or
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health plan, not an
individual
provider.

Bergman-Evans, (2013)

Evidence-based

N/A

To improve medication

Individuals at risk

Guideline

clinical

management practices

for problems with

guideline

by providers for older

A, based on

Strengths:

implemented

consistent and

Evidence-based

medications were

through use of

good-quality

medication

adults in the long-term

those who: self-treat,

Medication

patient

management for

care setting.

lack coordinated

Management

oriented

complex patients

care, were recently

Outcomes

evidence

with multiple

discharged from the

Monitor with 4

medical

hospital, have

outcomes: a)

conditions and

impaired cognitive

maintain function

medications;

status, and were on

b) decrease

highlights

complicated

polypharmacy c)

periodically

medication

avoid drug

checking

regimens.

adverse events d)

Creatinine

reduce

Clearance and

inappropriate

monitoring high

prescribing

risk drugs in older
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adults.
Weaknesses: Only
applies to longterm care
population, not
tested in primary
care setting;
polypharmacy
defined as nine or
more medications,
a different
definition than
found in the
literature.
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Abstract

Purpose: To develop and pilot an evidence-based protocol to address the problem of polypharmacy
in older adult patients seen in a primary care setting. This protocol will optimize safe and effective
medication prescribing and use, leading to improved patient care for the older adult patient and less
adverse events from polypharmacy.
Methods: A cross-sectional pilot study was conducted to assess nurse practitioner implementation of
the Polypharmacy Protocol to reduce polypharmacy and inappropriate prescribing in 20 patients,
ages 60 years and older, seen in a primary care setting. A process evaluation survey, a satisfaction
survey, and a fidelity assessment instrument were used to evaluate protocol implementation. Data
from the evaluation and satisfaction surveys were analyzed using descriptive statistics. For the
process evaluation and satisfaction surveys, summary scores were calculated.
Intervention: The Polypharmacy Protocol is an 8-step algorithm that systematically takes the
healthcare provider and patient through pertinent questions while reviewing a patient’s mediation list
to avoid polypharmacy and its adverse events.
Results: The mean score for the process evaluation was 3.08 (SD = .73) indicating that the protocol
was “Just right” in terms of usefulness. The mean score for satisfaction was 4 (SD = 0) indicating
that all Nurse Practitioners were very satisfied with the protocol. Qualitative feedback from the Nurse
Practitioners also supported the benefits of using the protocol.
Conclusion: The Polypharmacy Protocol piloted in this study was demonstrated to be an efficient
screening instrument that was feasible to use in primary care. In addition, the Nurse Practitioners
were highly satisfied with it when they used it. The protocol can be used routinely to guide
prescribing practice and reduce polypharmacy in older adult patients in primary care settings to
improve quality of life and decrease unfavorable medication events such as falls and hospitalizations.
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Introduction

Background and Significance
Older adult patients taking multiple medications is known as polypharmacy. The use of
screening instruments designed to reconcile a patient’s medication list for polypharmacy could
reduce adverse drug reactions and duplication of medications. Ultimately, this could lead to an
improvement in the older adult’s quality of life and decrease unfavorable drug events such as
falls and hospitalizations. The goal of this project was to develop an evidence-based protocol to
address the problem of polypharmacy in older adult patients seen in primary care. This protocol
will optimize safe and effective medication prescribing and use, leading to improved patient care
for the older adult and fewer adverse events from polypharmacy.
Older adult patients often take multiple medications for many health conditions which
results in polypharmacy. There is a lack of consensus on the definition of polypharmacy. The
most common definitions are “the use of potentially inappropriate drugs” and “the concurrent
use of five or more medications” including prescription and over the counter drugs (Bushardt,
Massey, Simpson, Ariail, & Simpson, 2008). The average older adult, defined as those aged 65
and older, has six chronic conditions that require multidrug therapy to cure, slow progression, or
reduce the symptoms of disease (Bushardt et al., 2008). Evidence based guidelines recommend
several drugs in the treatment or prevention of a single medical condition such as in the case of
diabetes mellitus or heart failure (Viktil, Blix, & Reikvam, 2008). Also, older adults tend to
consume more over the counter products than any other demographic group, accounting for 30%
of over the counter use in the U.S. (Francis, Barnett, & Denham, 2005; National Council on
Patient Information and Education, 2010). Consequently, this leads to the older adult patient
concurrently taking several medications, both prescription and over the counter. The relationship
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between the number of medications and the number of drug-related problems is linear, meaning
with each additional medication, the number of adverse reactions rises exponentially
(Zurakowski, 2009).
The U.S. Census Bureau projects that by the year 2020 there will be 55 million people
over age 65 which will represent 20% of the U.S population and who will account for 50% of
healthcare costs (Vincent & Velkoff, 2010). Prescriptions for the older adults, those age 65 years
and older, account for 25% to 40% of all prescriptions written in the United States (Ferrario,
2008). The increased number of medications used by a patient leads to an increased risk of
adverse drug reactions and events, poorer patient compliance, and a larger economic burden
(Bregnhoj, Thirstrup, Kristensen, Bjerrum, & Sonne, 2009). Adverse drug reactions and other
medication related problems such as falls and hospitalizations are associated with significant
mortality. Medications are associated with more than 100,000 deaths occur annually in the
United States at a cost of $85 billion each year (Bilyeu, Gumm, Fitzgerald, Fox, & Selig, 2011).
The relatively high rates of medication use by older adults--in combination with the physiologic
changes associated with aging such as decreased renal elimination, hepatic function, serum
albumin levels, total body water, and lean body mass--increase the prevalence of medication
associated mortality (Bushardt et al., 2008).
Patients over the age of 65 years see an average of seven healthcare providers
(Antimisiaris & Cheek, 2014). For older adults living with five or more chronic conditions this
number rises to 14 different healthcare providers, averaging over 40 office visits in one year
(Berenson, 2010). The utilization of specialist healthcare providers and the lack of
communication between multiple clinicians contributes to polypharmacy in the older adult
population (Riker & Setter, 2012). With an older adult patient visiting multiple healthcare
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providers and receiving several prescriptions, the patient is at risk for drug-drug and drug-disease
interactions along with side effects from each medication. Often times, the older adult patient can
be subjected to a phenomenon known as the “prescribing cascade” where a medication is added
to treat the side effect of another medication (Riker & Setter, 2012). This can happen when it is
not recognized that the initial medication is causing a side effect and the side effect is viewed as
a new symptom or disease and is therefore treated. Bootman, Harrsion, and Cox (1997) reported
that for every $1 spent on medications, $1.33 was spent on treating drug-related problems,
highlighting the significant problems and expenses polypharmacy can cause an older adult.
The use of medications has become essential for treating health conditions and
maintaining quality of life. When a medication is used incorrectly or prescribed inappropriately,
it can cause physical or psychological harm to a patient (Lam & Cheung, 2012). Inappropriate
prescribing is a blanket term for unregulated polypharmacy, under-prescribing, the prescription
of medications that have more potential risk then benefit, and poor prescribing practices by
healthcare providers that lead to adverse drug events (Penge & Crome, 2013). Inappropriate
prescribing can lead to increased healthcare utilization and expenditures. Appropriate prescribing
by a healthcare provider is the fundamental first step in the proper use of a medication (Lam &
Cheung, 2012).
Assessing and managing polypharmacy along with insuring appropriate prescribing in the
older adult patient can be overwhelming without a systematic approach. With the use of a
polypharmacy protocol, the healthcare provider will be able to evaluate a patient’s medication
list and make appropriate changes to decrease polypharmacy and its adverse events thus
improving quality of care and enhancing safe prescribing practices. The purpose of this pilot
study was to test an evidence-based research protocol to address polypharmacy in the primary
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care setting. This included assessing its feasibility to gauge whether or not it is realistic for use in
the primary care setting.
Objectives
The objectives of this study were to:
1. Conduct a medication review with the Polypharmacy Protocol to modify the patients’
regimen, where indicated, to reduce polypharmacy.
2. Assess nurse practitioners’ prescribing habits to identify inappropriate prescription of
medications to older adults that may lead to adverse events.
3. Evaluate the implementation of the Polypharmacy Protocol with a process evaluation survey,
a satisfaction survey, and a fidelity assessment instrument (i.e., the extent to which delivery
of the intervention adhered to the protocol).
Review of Literature
Using the key words “protocol,” “guideline,” “geriatrics,” “elderly,” “older adult,”
“polypharmacy,” and “primary care,” the OVID, CINAHL, EBSCO, Cochrane Library,
MEDLINE, and PubMed databases were searched. Inclusion criteria were: articles in medical,
nursing, and pharmacology journals with a protocol or clinical practice guideline or other clinical
strategy for polypharmacy that led to fewer adverse drug events as the outcome variable. A
clinical practice guideline is designed to support decision-making processes in patient care with
content based on a systematic review of the clinical evidence. A protocol is viewed as more
specific than a guideline, as it provides a comprehensive set of criteria outlining the management
steps for a single clinical condition (Field & Lohr, 1992). Qualitative and quantitative studies
were included. Articles published in the 15-year period from 1998 through 2013 were chosen for
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review of the most current state of the evidence. One article published in 1992 was included
because it contained a documented screening instrument for practice.
Sixteen articles met the criteria for inclusion in this review. The articles described a broad
range of approaches to address polypharmacy in the older adult including: screening instruments
to reduce the prescription of inappropriate medications by healthcare professionals, expert
clinical opinion strategies or recommendations, an algorithm for reducing or discontinuing
medications, mnemonics for use by clinicians while reconciling a medication list, and clinical
practice guidelines. The articles were reviewed using the categories of: (a) author (date); (b) type
of study; (c) sample; (d) purpose; (e) findings; (f) implications; (g) evidence level; and (h)
strength of evidence. They were further grouped into subheadings of: Clinical Strategies,
Algorithms, Acronyms, Guidelines, and Screening Instruments. The Hierarchy of Evidence
Rating System used was the Strength of Recommendation Taxonomy (SORT) (Ebell et al.,
2004). This system rates the evidence from Levels A to C, with Level A being consistent, goodquality patient-oriented evidence. Level B is inconsistent or limited-quality patient-oriented
evidence, and Level C is consensus, disease-oriented evidence. The SORT system also is used to
assess the quality of evidence of the studies where Level I is the highest and Level III is the
lowest. Key findings from the articles are summarized in the manuscript, A Literature Review:
Polypharmacy Protocol for Primary Care, published in Geriatric Nursing (Skinner, 2015).
Methods
Design
A cross-sectional pilot study was conducted between April and July 2015 to assess nurse
practitioner implementation of the polypharmacy protocol to reduce polypharmacy and
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inappropriate prescribing in older adults, age 60 years and older, seen in a primary care setting.
Setting
The pilot study was conducted at a primary care clinic in Louisville, KY. The Kentucky
Racing Health Service Center (KRHSC) is an independent clinic not affiliated with a specific
medical system. The clinic provides health care services for the uninsured, migrant workers that
look after and train thoroughbred horses at Churchill Downs. At the KRHSC, there are three
exam rooms complete with computers for documentation and equipment to complete physical
exams. Staff and personnel include four Nurse Practitioners and a Spanish interpreter. The four
Nurse Practitioners have 2-10 years of experience as Primary Care Providers. The Spanish
interpreters are either from Hispanic backgrounds or are Foreign Language graduates in Spanish.
All are fluent in both English and Spanish are always on site during clinic hours. The clinic
offers full primary care services including prescriptions, lab work, diagnostic testing, and
referrals to specialists when needed.
Sample
There were two study samples, (1) the patients who meet the age and polypharmacy
criteria and (2) the Nurse Practitioners. The data on the purposive sample of patients were
collected. Four Nurse Practitioners in the primary care clinic piloted the Polypharmacy Protocol
on five patients each for a total of 20 patients who used five or more medications per day. Male
and female adult patients age 60 years and older were included. The lower boundary of 60 years
of age was set due to the large number of adult patients in the primary care clinic who consume
greater than five medications daily and could benefit from participating in this pilot study. The
primary care clinic predominately serves a Hispanic population in Louisville, KY, but African
American and Caucasian patients were seen as well. Patients at this clinic have a variety of
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common chronic diseases such as hypertension, dyslipidemia, type 2 diabetes, and chronic
obstructive pulmonary disease that require treatment with multiple medications.
Inclusion criteria for the patients were: The use of five or more medications per day and
age 60 years or older. Exclusion criteria for the patients were: Any patient who had moderate to
severe cognitive impairment (dementia). Cognition was evaluated by the Principal Investigator
with the Mini-Cog screening instrument (see Appendices) prior to using the polypharmacy
protocol. There are three parts to the Mini-Cog that are totaled. A score of 0-2 indicates a
positive screen for dementia, while a score of 3-5 is a negative screen for dementia. The MiniCog (Borson, Scanlan, Brush, Vitaliano, & Dokmak, 2000) was developed as a brief screening
tool to differentiate patients with dementia from those without dementia. It takes approximately
three minutes to administer. The Clock Drawing Test (CDT) component of the Mini-Cog allows
clinicians to quickly assess numerous cognitive domains including cognitive function, memory,
language comprehension, visual-motor skills, and executive function and provides a visible
record of both normal and impaired performance that can be tracked over time. Depending on the
prevalence of dementia in the target population, the Mini-Cog has sensitivity ranging from 76%99%, and specificity ranging from 89%-93% with a 95% confidence interval. This tool has
strong predictive value in multiple clinical settings (Borson et al., 2003). A score of 3-5 out of 5
is a negative screen for dementia (Borson et al., 2006), whereas a score of 0-2 out of 5 indicates
mild cognitive impairment (McCarten et al., 2012).
The Mini-Cog has been shown to identify early dementia in nonnative and non-English
speakers as well as in native English speakers (Doerfinger, 2007). Borson et al. (2000) conducted
additional testing to examine the tool's accuracy in a "community sample of culturally,
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linguistically, and educationally heterogeneous older adults" (N = 249). Researchers tested 129
subjects who met the clinical criteria for probable dementia based on interviews and 120 subjects
who had no history of cognitive impairment. There were 124 non-English speakers in the
sample. The sample was 22% African American, 48% Asian American, 17% Hispanic, 7% white
non-Hispanic, and 6% Native American and other. The Mini-Cog was compared with the MMSE
and the Cognitive Abilities Screening Instrument (CASI). The Mini-Cog correctly identified
96% of subjects--more than either of the other tools. It also had the highest sensitivity at 99% (P
< 0.001). The researchers noted that the Mini-Cog's diagnostic value was not influenced by
education or language (Borson et al., 2000). The Mini-Cog has been tested in multiethnic and
multilingual populations without being formally translated (Borson et al., 2000).! !
Inclusion criteria for the Nurse Practitioners were: hold a Master of Science in Nursing or
Doctorate in Nursing Practice and licensed as an Advanced Practice Registered Nurse (APRN) in
the state of Kentucky. Those who practiced at the clinic less than 8 hours per week were
excluded. The four Nurse Practitioners were approached about participation in this pilot study.
All agreed to participate after the purpose of the pilot study was described.
Measures
The Polypharmacy Protocol implementation in the community primary care clinic was
evaluated. This included formative and summative questions as part of a process evaluation to
determine if the protocol changed the nurse practitioner’s review of the patient’s medication list
to reduce polypharmacy and improved their prescribing habits with older adult patients. The
purpose of this process evaluation was to determine if the Polypharmacy Protocol assisted the
Nurse Practitioners in identifying polypharmacy and potential adverse events. The Nurse
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Practitioners also evaluated their satisfaction with the protocol. The four Nurse Practitioners in
the primary care clinic were asked to complete the process evaluation instrument and satisfaction
survey after using the protocol with five patients apiece.
Specifically, three questions were asked:
1. Is the Polypharmacy Protocol feasible to use in your primary care practice with older
adults? Feedback was requested with any negative responses (not nearly enough, not
quite enough) as to why the protocol is not feasible for the primary care setting.
2. How do you rate your satisfaction with the Polypharmacy Protocol? Recommendations
or suggestions for improvement for future use were requested.
3. How much time did it take to administer the protocol? Time can be a factor in how well
the protocol was adopted and recommendations were requested on how to make the
protocol efficient in a timely manner for future use.
The process evaluation survey outlined in the Appendices was a new instrument created
specifically for the Polypharmacy Protocol pilot study. Two PhD prepared nurse researchers with
expertise in survey development and epidemiology reviewed the survey. To improve the validity
of the protocol, the Principal Investigator was present for each patient visit to ensure the Nurse
Practitioners consistently administered the Polypharmacy Protocol. Once the pilot study was
completed, each of the Nurse Practitioners were asked for feedback to identify ambiguities and
difficult questions along with recording the time taken to complete the protocol.
Once the medication review with the Polypharmacy Protocol was completed for all 20
patients, the Nurse Practitioners completed the two surveys. The first survey provided ordinal
level data using a Likert scale for feedback on protocol implementation along with
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recommendations for improvement for future use. The second survey provided ordinal level data
on their contentment or satisfaction with the protocol using a Likert scale. The Principal
Investigator used the fidelity assessment instrument created specifically for this pilot study
during chart audits after implementation of the Polypharmacy Protocol to assess the extent to
which delivery by the Nurse Practitioners adhered to the originally developed protocol. The
fidelity assessment determined if adjustments to a patient’s medication regimen were made by
the Nurse Practitioner to avoid polypharmacy. Examples of questions included in the fidelity
instrument were: inquiring about OTC medications, if any new medications had been added by a
specialist or to treat another symptom of a disease, and to remove or decrease the dose of any
high-risk medications that have been deemed by the American Geriatrics Society as having the
most adverse effects.
The Appendices contain the instruments used in the pilot study. Table 1 describes the
Process Evaluation instrument used by the Nurse Practitioners after implementation of the
Polypharmacy Protocol. Table 2 outlines the survey that assessed the Nurse Practitioners’
satisfaction in using the Polypharmacy Protocol. Four questions were adapted from the Client
Satisfaction Questionnaire CSQ-8 (Attkisson, & Zwick, 1982). The CSQ-8 is a reliable and
valid measure of client satisfaction with services or programs; Cronbach’s alpha was .93
(Attkisson, & Zwick, 1982). Table 3 provides three questions that were part of the fidelity
assessment instrument. Table 4 includes the measures.
Intervention Protocol
The Polypharmacy Protocol is an 8-step algorithm based on the review of the literature
findings (see Skinner, 2015). The pertinent conclusions from the review of literature were placed
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into the algorithm to systematically take the Nurse Practitioner and patient through pertinent
questions while reviewing the patient’s medication list to avoid polypharmacy and its adverse
events. The questions included: (1) inquiring about the use of over the counter products; (2)
whether or not the patient sees a specialist or specialists and/or has been recently discharged
from the hospital; (3) if a medication has been recently added to the regimen to treat the side
effect of another medication (the prescribing cascade); (4) are there any duplications of
medications on the list; (5) is the patient consuming any high risk medications as identified by
the American Geriatrics Society; (6) does each drug in the regimen have a clear indication; (7)
does the patient exhibit any physiologic changes associated with aging that could potentially
cause an adverse reaction; (8) and is the patient taking the lowest therapeutic dose of each
medication. Each step in the protocol has a clear path based on the patient’s yes or no response,
including what to do if a medication is discontinued from the list with consulting the specialist,
monitoring the patient, and reassessing the patient with a follow-up visit. The Polypharmacy
Protocol for Primary Care can be found in the Appendices.
Procedure
The proposal was approved in March 2015 by the University of Kentucky Medical
Institutional Review Board. The Principal Investigator obtained written informed consent from
the four Nurse Practitioners who agreed to use the Polypharmacy Protocol with five patients
each. No cold calls or direct mailings were conducted to recruit patients. During a scheduled
office visit, the patients who met screening eligibility were approached by the Principal
Investigator about the pilot study. In order to avoid coercion, the patients were assured that their
participation was voluntary and they would not suffer negative consequences involving their
continued care at the clinic if they chose not to participate. If they chose to participate, they
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could stop at any time during the study and still keep the benefits and rights they had before
volunteering. If the patient agreed to participate, the Principal Investigator obtained written
informed consent in their native language (Spanish or English).
After the consent form was signed in their native language, the Principal Investigator
completed the Mini-Cog instrument to assess for cognitive impairment. Every patient scored
between 3-5, indicating a negative outcome for cognitive impairment based on recalling three
objects and drawing the face of a clock appropriately.
Once consent was obtained and the Mini-Cog was completed, each patient was randomly
seen by one of the four Nurse Practitioners in the clinic. The patients were requested to bring in
their home medication list and/or bottles with them to their next scheduled office visit. At that
visit, the Nurse Practitioner: (1) used the protocol to review the patient’s medication list; (2)
made appropriate adjustments to reduce the adverse effects of polypharmacy; and (3) assessed
their own prescribing habits for inappropriate medications. If needed, in order to ensure the
medication information obtained from the patient was accurate, the nurse practitioner contacted
the pharmacy where the medications were filled to verify medication the name, dosage, and last
time the medication was filled by the patient.
Privacy of the patients was insured with no use of patient identifiers. Each patient who
agreed to participate and signed an informed consent form was assigned a study number that
correlates with the Nurse Practitioner who saw the patient. For example, NP #1’s five patients
were coded as: NP1-1, NP1-2, NP1-3, NP1-4, and NP1-5. This numbering system continued for
each of the four Nurse Practitioners and their five patients apiece. After the Principal Investigator
obtained informed consent from the patients, the consent forms were locked in a file cabinet in a
secure location at the primary care clinic.
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Privacy of the four Nurse Practitioners was insured with no identifiers such as name or

license number on the two surveys they completed after using the Polypharmacy Protocol with
their five patients. The Nurse Practitioners’ informed consent forms were locked in a file cabinet
in a secure location at the primary care clinic. The Nurse Practitioners completed the two surveys
after completing the Polypharmacy Protocol with their fifth patient. The Principal Investigator
completed chart audits after implementation of the Polypharmacy Protocol to assess for fidelity
or the extent to which delivery of the Polypharmacy Protocol by the Nurse Practitioners adhered
to the originally developed protocol. Data were analyzed using descriptive statistics including
frequency distributions, measures of central tendency (mean, median and/or mode) for the 4point Likert scales. For the process evaluation, summary scores for all of the questions on the
survey were derived and means were calculated.
Results
Demographic information for the 20 patients who participated in the pilot study included:
five African Americans, four Caucasians, and 11 Hispanics. The male to female ratio was 14:6
with the male age range between 60-71 and the female age range between 60-66. Each patient
had a minimum of five medications while the highest number found on a regimen was seven
prescription medications. One patient had a total of 10 medications, four prescribed and six OTC
products including vitamins and herbal preparations. The most commonly prescribed
medications found during the pilot study included ACE-inhibitors and Calcium Channel
Blockers for hypertension, Metformin for treatment of type 2 diabetes, and the family of
cholesterol drugs known as the statins. The most common OTC medications found during the
pilot study were NSAIDs (Ibuprofen, Naproxen, and Tylenol), Calcium plus Vitamin D along
with antacids such as omeprazole.

70!

!

!
!
!
!
!

!
!
!

!
!

!
!

!

!

The Nurse Practitioners used all eight steps of the Polypharmacy Protocol correctly when
reviewing the patient’s medication list. Table 1 describes the changes made to the patient’s
medication regimen by the Nurse Practitioners using the protocol. This information was
collected during the chart audits using the fidelity instrument, post-implementation of the
protocol.
Table 1. Fidelity Instrument for the Polypharmacy Protocol Pilot Study Results
Question

Change

Were OTC medications added to the med list?

OTC products such as Multi-vitamins and
Tylenol were added to 3 out of 20 charts

Was a note made about specialist or recent
discharge from hospital with changes to med
list?

Medication lists were updated based on a
patient’s recent discharge from the hospital
for 2 patients

Was the medication list reviewed and adjusted
for: Prescribing cascade?

No adjustments were made for problems
related to the Prescribing Cascade as no
issues were identified.
Duplicate medications were removed from
2 patients’ medication lists

Was the medication list reviewed and adjusted
for: Duplications?
Was the medication list reviewed and adjusted
for: High-risk medications from Table 2?

Was the medication list reviewed and adjusted
for: Matched medication with diagnosis?
Was the medication list reviewed and adjusted
for: Note any physiologic changes in the
patient?
Was the medication list reviewed and adjusted
for: Decrease dose to lowest effective dose?

All patient lists were compared with the
high-risk medications from Table 2 leading
to removal of NSAIDs from 2 patients’ lists
and switching 1 patient’s glyburide to
another diabetic medication.
All patient medications were matched with
an appropriate diagnosis.
Each patient either had recent or was asked
to have blood work drawn to look for renal,
liver and protein changes that could affect
the pharmacokinetics
3 patient medications were decreased to the
lowest effective dose and monitored closely
(Ambien, Ultram, Glipizide)
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Results for each survey item on the process evaluation are listed in Table 2. For Nurse
Practitioner satisfaction, summary scores for the four questions adapted from the CSQ-8 were
calculated and had a mean of 4 (SD = 0.0) indicating there was perfect agreement across all four
Nurse Practitioners in terms of high satisfaction with the protocol. Results for each item on the
satisfaction survey are listed in Table 3. Qualitative feedback from the Nurse Practitioners on the
use of the Polypharmacy Protocol is summarized in Table 4.
Table 2. Mean and Standard Deviation for Process Evaluation Items (N = 4)
Item

Mean

Does the protocol include enough background
information about the problem of
polypharmacy and inappropriate prescribing?

3

Standard
Deviation
0.0

Does the protocol allow the APRN freedom to
individualize the protocol for each patient’s
medication list review?

3.25

0.5

Is the protocol feasible/appropriate for an
APRN in this practice setting?

3

0.0

Does the protocol provide the minimum
standard of care for the clinical problem of
polypharmacy?

3

0.0

Does the protocol provide the minimum
standard of care for addressing inappropriate
prescribing in the older adult population?

3

0.0

How much time did it take to administer the
protocol?

3.25

0.96
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Table 3. Mean and Standard Deviation for Satisfaction Items (N = 4)
Item

Mean

!
!

!

How would you rate the quality of the
Polypharmacy Protocol?

4

Standard
Deviation
0.0

To what extent did the Polypharmacy Protocol
meet the needs of your practice setting?

4

0.0

Did the Polypharmacy Protocol help you
address the problem of polypharmacy and
inappropriate prescribing in your practice
setting?

4

0.0

Overall, how satisfied are you with the
Polypharmacy Protocol in addressing
polypharmacy and inappropriate prescribing in
your practice setting?

4

0.0

Table 4. Qualitative feedback from the Nurse Practitioners on the use of the
Polypharmacy Protocol (N = 4)
1. Do you feel that the protocol made you more aware of the problem of polypharmacy
and its problems?
•
•
•

It simplified the Beers criteria
Having an algorithm really helped streamline the medication review
The protocol re-emphasized potential drug-drug interactions

2. Do you feel that the protocol modified your prescribing habits to avoid inappropriate
prescribing in older adults?
•
•
•
•

It made me more aware of the over-the-counter interactions
Made me more aware of problem drugs
Helped to remind me to ask about over-the-counter medications at every visit
Helped me to identify drug side effects

3. What are the best features of the protocol?
•
•
•
•

Ease of use
Protocol is clear
The flow of the algorithm with tables to guide your interview
Provided a defined process to logically assess a patient’s medication list
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4. What are the worst features of the protocol?
•
•

Trying to explain to the patient your reason for doing the protocol as part of their
visit
None

5. Please list any suggestions you have to improve or change the protocol for use in
practice.
• Needs medication reconciliation as part of Step 1
• Ask about adherence to medications in Step 1
• Change Step 2 to specialist or other provider who has prescribed medications
• Add Emergency Room and Urgent Care to Step 2
• Quantify the term recently in Step 3 as last month/week, since last visit, etc.
• Define the term prescribing cascade in Step 4 because not all providers are aware
of this phrase
• Consider adding to Step 8 titration of medication to most effective dose (as in the
case of titration of medications to therapeutic dose for medications such as Beta
Blockers and ACE-inhibitors for Heart Failure patients)
• Consider adding a Step that asks about the patient’s wishes or preferences
• Consider adding a Step that takes cost of medication into account

Discussion
The Polypharmacy Protocol is feasible for use in the primary care practice with older
adults and received high satisfaction ratings from the Nurse Practitioners. However, time was an
implementation factor with varying ranges reported by the Nurse Practitioners. Time is an
important element to consider when initiating a protocol especially in the primary care setting
where patient visit times can be brief and other issues may take precedence. If the Polypharmacy
Protocol became part of an Electronic Medical Record (EMR) a provider could simply scroll
through the algorithm as he or she reviews a patient’s medication list, checking yes or no boxes,
leading to a quicker review process. Goals for the future with the Polypharmacy Protocol include
investigating software to incorporate it into an EMR or an application for a smart phone.
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The qualitative responses from the pilot study participants yielded the most valuable

findings. Based on the Nurse Practitioner’s responses to both surveys, the Polypharmacy
Protocol was reviewed to either discard or revise all unnecessary or ambiguous questions and
assess whether each question gave an adequate range of responses to establish replies from
patients that can be interpreted in terms of the information that is necessary to reduce
polypharmacy. Revisions to the Polypharmacy Protocol based on the feedback will include:
verifying that what is in the chart is what the patient is currently taking and inquiring about
medication adherence in Step 1; adding other providers who have prescribed medications along
with recent Emergency Room or Urgent Care visit to Step 2; quantifying the term “recently” in
Step 3 to reflect time since the patient’s last visit in the primary care office or clinic; define the
term “prescribing cascade” in Step 4 as a recently prescribed medication is causing a side effect
and the side effect is viewed as a new symptom and therefore treated; supplement Step 8, to
include therapeutic doses for specific disease states; adding a step that prompts the provider to
ask about the patient’s preferences or wishes regarding their medication regimen; and inserting a
final step that features inquiring about the cost of medications for the patient.
Limitations
!

Pilot studies are exploratory trials limited in size and scope that give insight into research

protocols, medications, or medical devices but cannot provide definitive support for specific
systematic or therapeutic claims (Polit et al., 2001). Individual small-sized studies include
assessing feasibility, determining potential harm, validating a method for determining an
outcome measure, and evaluating the organization of the pilot study performance (Loscalzo,
2009). However, there are associated disadvantages or limitations of pilot studies. The feasibility
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and acceptability may be misleading if the size is small leading to inadequate power to detect
harm or other problems (Loscalzo, 2009). Further, a study can only examine feasibility of the
patient type included in the study making generalizability of the results difficult beyond the
inclusion and exclusion criteria of the pilot (Loscalzo, 2009). This was the case with the
Polypharmacy Protocol Pilot Study; it was tested in a single setting with a small number of
patients and healthcare providers.
A pilot study is not a hypothesis testing study and therefore safety and efficacy are not
evaluated (Leon, Davis, & Kraemer, 2011). However, a pilot study can be clinically meaningful
if it requires contributions from clinicians who treat the patient population of interest (Leon et
al., 2011). The Polypharmacy Protocol pilot study was conducted with the goal of seeking the
input of healthcare providers wanting to improve their practice by avoiding polypharmacy in
their older adult patients. To ensure that the interpretation of a pilot study is reliable, it must be
approached rigorously and with the same level of scrutiny as other trials (Loscalzo, 2009). The
outcomes for the Polypharmacy Protocol pilot study were outlined practically to avoid
misinterpretation of the results.
Additional limitations specific to this pilot study include the highly motivated Nurse
Practitioners who wanted to see the protocol be successful, the demographics of the patient
population and the nature of the clinic. The KRHSC fulfills a need in the community for the
migrant workers in the thoroughbred racing industry who typically only seek care while in
Louisville, KY. Also, there are differences in the prescribing habits of the providers. Due to not
billing insurance companies or having access to samples of medications from drug companies,
the providers primarily prescribe from the generic $4 or $10 medication lists available from local
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retailers. These types of prescribing habits may not be generalizable to the primary care clinics in
other areas of the United States.
In summary, pilot studies are a necessary first step in exploring new interventions, such
as a protocol, that are designed to inform the healthcare community of its feasibility. Once
completed, the intervention can be modified for a larger trial to evaluate its safety and efficacy.
After revisions are completed on the Polypharmacy Protocol, the next step will be to test it in a
larger setting such as several community primary care clinics that care for a variety of older adult
patients.
Conclusion
There is a need for a simple, time-efficient screening protocol that can be used routinely
to guide prescribing practice and reduce polypharmacy in older adult patients in primary care
settings. Protocols are designed as a standardized way of performing a task that is repeatable and
reproducible. The goals of protocols were to produce similar results, provide a consistent
presentation of data and confidence in results, allow for efficient auditing procedures, and
possibly prevents errors (Loscalzo, 2009). To address polypharmacy in primary care, such a
protocol should be sensitive, specific, include commonly encountered adverse drug events,
translate into positive clinical outcomes, and have good inter-rater reliability (Hamilton et al.,
2009). The Polypharmacy Protocol piloted in this study encompasses these attributes and
provides a strategy that can be incorporated into practice to reduce adverse drug reactions,
improve an older adult’s quality of life, and decrease unfavorable events such as falls and
hospitalizations.
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Appendix
Figure 1. Polypharmacy Protocol for Primary Care
Purpose: To address the problem of polypharmacy and inappropriate prescribing in older adult
patients (age 60 and older) seen in a primary care setting. This protocol will provide a systematic
approach for the healthcare provider to evaluate a patient’s medication list and make appropriate
changes to decrease polypharmacy. It will also optimize safe and effective medication prescribing by
the healthcare provider leading to improved patient care for the older adult and less adverse drug
events.

Definitions:
•

Polypharmacy—“the use of potentially inappropriate drugs” and “the concurrent use of five
or more medications” including prescription and over the counter drugs

•

Inappropriate Prescribing in Older Adults--unregulated polypharmacy, the prescription of
medications that have more potential risk then benefit, and poor prescribing practices by
healthcare providers that lead to adverse drug events.
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Polypharmacy+Protocol+for+Primary+Care+
!

Obtain'pa)ent'medica)on'
List/Brown'Bag'

STEP'1'
Take'any'OTC'products?'
(vitamins,'minerals,'herbs)'

YES'
Add'OTC'products'to'medica)on'list'
Note%any%drug-drug%interac0ons?%
%
Common'OTCHprescrip)on'interac)ons'
'1.'St.'John's'Wort'+'SSRI'or'Tricyclic'
An)depressants'
'2.'Tylenol'+'Lortab/Vicodin'
'3.'Antacids'+'Levothyroxine'and'Iron'
supplements'
'4.'Omeprazole'+'Plavix'
'5.'Coumadin'+'Aspirin'or'Gingko'or'Kava'

NO'
Go'To'Step'2'

STEP'2'
See'any'specialists?''
OR'
Discharged'from'hospital'
recently?'

The'Gerontological'Society'of'America,'2013'

YES'
Update'medica)on'list'with'meds'
from'specialist'or'hospital'
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Go'To'STEP'3'
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STEP'3'
Was'a'medica)on'added'recently'to'treat'the'side'eﬀect'of'another'medica)on?'
"The'Prescribing'Cascade"'
Ex.'BP'med'for'chronic'NSAID'user''
Ex.'Detrol'for'incon)nence'from'Aricept'
Ex.'An)Hparkinson'med'for'symptoms'from'Reglan'
An)misiari'&'Cheek,'2014'

YES'
Stop'medica)on,'monitor'pa)ent,'and'reassess''

NO'
GO'TO'STEP'4'

in'1H2'weeks'
(See'Table'1'for'monitoring'guidelines,'
see'Table'3'for'consul)ng'specialists)'

TABLE+1+
What'to'monitor'on'a'patient'after'
adjusting'dose'or'discontinuing'
medication:'
'
1. Heart'rate'
2. Blood'pressure,'including'
orthostatic'
3. Oxygen'saturation'
4. Weight'
5. Appetite'
6. Sleep'
7. Activity,'including'falls'
8. Bowel/bladder'function'

STEP'4'
Any'duplica)on'of'medica)ons?'
(same'class)'
Ex.'Lortab/Vicodin'+'Tylenol'ES'
Ex.'Toprol'XL'+'metoprolol'tartrate'
Ex.'Glipizide'+'Glimepiride'

Haque,'2009'

'
YES'
Discon)nue'duplicates;'monitor'
pa)ent'and'reassess'in'1H2'weeks'
(See'Table'1'for'monitoring'
guidelines)'
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STEP'5'
Note'any'high'risk/dangerous'medica)ons?'
(compare'to'Table'2)'

YES'
If'reasonable,'reduce'dose/stop'high'risk''
medica)on'or'switch'to'safer'drug;'mon)or'pa)ent'

NO''
GO'TO'STEP'6'

and'reassess'in'1H2'weeks'
(see'Table'1'for'monitoring'guidelines,'
see'Table'3'for'consul)ng'specialists)'

!

!
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TABLE+2+
10'Medications'to'Avoid'or'Use'Caution'in'Older'Adults'
'

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

NSAIDs'
• Especially'with'blood'thinners,'such'as'Coumadin'
Lanoxin'(digoxin)'
Sulfonylureas'(Glyburide,'chlorpropamide)'
Muscle'Relaxants'(Flexeril,'Robaxin,'Soma)'
Anxiety/Insomnia'(Valium,'Xanax,'Librium,'Sonata,'Ambien)'
Anticholinergic'Drugs'(Amitriptyline,'Bentyl,'oxybutynin)'
Demerol'
OTC'Drugs'(Benadryl,'chlorpheniramine,'Tylenol'PM)'
Antipsychotics'(Haldol,'Risperdal,'Seroquel)'
Estrogen'pills/patches''

American'Geriatrics'Society,'2012'

'
***Please'note:'If'discontinuing'a'psychoactive'drug'(antidepressant,'antipsychotic,'neuralgia'
medications,'pain'medications,'and'anticonvulsants)'taper'the'dose'to'avoid'adverse'
withdrawal'effects.'

'
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STEP'6'
Does'each'drug'have'a'clear'
indica)on?'
(Diagnosis'matchs'medica)on)'
NO'
Discon)nue'medica)on(s)'that'
do'not'match'a'diagnosis;'
monitor'pa)ent'and'reassess'in'
1H2'weeks.'

YES'
GO'TO'STEP'7'

(see'Table'1'for'monitoring'
guidelines,'see'Table'3'for'
consul)ng'specialists)'

STEP'7'
Does'pa)ent'exhibit'any'physiologic'changes'
of'aging'that'could'lead'to'poten)al'adverse'
reac)ons?'
1.'Reduced'GFR/Cr'Clearance'
2.'Elevated'liver'enzymes'
3.'Decreased'serum'albumin'

YES'
Reduce'dose'of'medica)on;'
monitor'pa)ent'and''reassess'
pa)ent'in'1H2'weeks'

NO'
GO'TO'STEP'8'

(see'Table'1'for'monitoring'
guidelines,'see'Table'3'for'
consul)ng'specialists)'
STEP'8''
Is'the'pa)ent'taking'the'
lowest'therapeu)c/'
eﬀec)ve'dose?'

YES''
Polypharmacy'
Review'Complete'

NO''
Reduce'dose'of'one'medica)ion'
at'a')me;'monitor'pa)ent'and'
reasses'in'1H'2'weeks'
(see'Table'1'for'monitoring'
guidelines,'see'Table'3'for'
consutling'specialists)'

!
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Table+3+
+
When'to'consult'specialists'regarding'withdrawal'of'medications:'
'
1. ACE'inhibitors'for'HF'
2. Diuretics'for'HF'
3. Essential'hormones'(longHterm'corticosteroids,'levothyroxine)'
4. Antipsychotics,'mood'stabilizing'drugs'
5. Anticonvulsants'for'seizures'
6. Parkinson’s'medications'
7. Disease'modifying'antiHrheumatic'drugs'
8. Longstanding'benzodiazepines'and'opiates'
CNA,'2013'

'
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Figure 2. The Mini Cog
Administration:
1. Instruct the patient to listen carefully to and remember 3 unrelated words and then to
repeat the words. The same 3 words may be repeated to the patient up to 3 tries to register
all 3 words.
2. Instruct the patient to draw the face of a clock, either on a blank sheet of paper or on a
sheet with the clock circle already drawn on the page. After the patient puts the numbers
on the clock face, ask him or her to draw the hands of the clock to read a specific time.
The time 11:10 has demonstrated increased sensitivity.
3. Ask the patient to repeat the 3 previously stated words.
Scoring: (Out of total of 5 points)
•
•

Give 1 point for each recalled word after the CDT distractor. Recall is scored 0-3.
The CDT distractor is scored 2 if normal and 0 if abnormal.
(Note: The CDT is considered normal if all numbers are present in the correct sequence
and position, and the hands readably display the requested time. Length of hands is not
considered in the score.)

Interpretation of Results:
0-2: Positive screen for dementia
3-5: Negative screen for dementia
Sources:
Borson, S., Scanlan, J., Brush, M., Vitallano, P., & Dokmak, A. (2000). The Mini-Cog: A cognitive ‘vital signs’ measure for
dementia screening in multi-lingual elderly. International Journal of Geriatric Psychiatry, 15(11), 1021-1027.
Borson, S., Scanlan, J.M., Watanabe, J., Tu, S.P., & Lessig, M. (2006). Improving identification of cognitive impairment in
primary care. International Journal of Geriatric Psychiatry, 21(4), 349-355.
Lessig, M., Scanlan, J., Nazemi, H., & Borson, S. (2008). Time that tells: Critical clock-drawing errors for dementia screening.
International Psychogeriatrics, 20(3), 459-470.
Copyright S. Borson. All rights reserved. Reprinted with permission.
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Table 1. Process Evaluation
Question
Does the protocol include enough
background information about the
problem of polypharmacy and
inappropriate prescribing?

!
!
!

!
!

!
!

!

!

Not nearly
enough
1

Not quite
enough
2

Just
right
3

More than
enough
4

Does the protocol allow the APRN
freedom to individualize the
protocol for each patient’s
medication list review?

Not nearly
enough
1

Not quite
enough
2

Just
right
3

More than
enough
4

Is the protocol feasible/appropriate
for an APRN in this practice
setting?

Not nearly
enough
1

Not quite
enough
2

Just
right
3

More than
enough
4

Why not?

Why not?

Does the protocol provide the
minimum standard of care for the
clinical problem of polypharmacy?

Not nearly
enough
1

Not quite
enough
2

Just
right
3

More than
enough
4

Does the protocol provide the
minimum standard of care for
addressing inappropriate prescribing
in the older adult population?

Not nearly
enough
1

Not quite
enough
2

Just
right
3

More than
enough
4

How much time did it take to
administer the protocol? (circle one)

25-30
minutes
1
Yes or No

20-25
minutes
2

15-20
minutes
3

10-15
minutes
4

Feedback:
Do you feel that the protocol made
you more aware of the problem of
Why or Why
polypharmacy and its complications?
not?
Feedback:
Do you feel that the protocol
modified your prescribing habits to
Yes or No
avoid inappropriate prescribing in
older adults?
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Why or why not?

!
!
!
!
!
Feedback:
What are the best features of the
protocol?
Feedback:
What are the worst features of the
protocol?
Feedback:
Please list any suggestions you have
to improve or change the protocol
for use in practice.

!
!
!

!
!
!

Adapted from: Paul, S. (1999). Developing practice protocols for advanced practice nursing. AACN Clinical Issues, 10(3), 343-55.
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Table 2. Nurse Practitioner Satisfaction with the Polypharmacy Protocol Implementation Survey
Question
How would you rate the
quality of the Polypharmacy
Protocol?

Poor
1

Fair
2

Good
3

Excellent
4

To what extent did the
Polypharmacy Protocol meet
the needs of your practice
setting?

None of my
needs have
been met
1

Only a few of
my needs have
been met
2

Most of my
needs have
been met
3

Almost all of
my needs
have been met
4

Did the Polypharmacy
Protocol help you address the
problem of polypharmacy and
inappropriate prescribing in
your practice setting?
Overall, how satisfied are you
with the Polypharmacy
Protocol in addressing
polypharmacy and
inappropriate prescribing in
your practice setting?

Didn’t help

Helped some

1

2

Helped a
good bit
3

Helped a great
deal
4

Very
dissatisfied
1

Dissatisfied

Mostly
satisfied
3

Very
satisfied
4

2

Adapted from: Client Satisfaction Questionnaire (CSQ-8). (Attkisson, & Zwick, 1982).
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Table 3. Fidelity Instrument for the Polypharmacy Protocol Pilot Study

!
!

!
!
!

1. Are the Nurse Practitioners using the Polypharmacy Protocol correctly when reviewing the
patient’s medication list?
Circle the appropriate percentage:
• 100% of the time (used all 8 steps of the protocol)
• 88% of the time (used 7 steps of the protocol)
• 75% of the time (used 6 steps of the protocol)
• 63% of the time (used 5 steps of the protocol)
• 50% of the time (used 4 steps of the protocol)
• 38% of the time (used 3 steps of the protocol)
• 25% of the time (used 2 steps of the protocol)
• 13% of the time (used 1 step of the protocol)
2. What types of adjustments were made by the Nurse Practitioners to the patient’s medication list
to reduce polypharmacy while using the protocol?
Check Yes or No
Question
Were OTC medications added to the med list?

Yes

Was a note made about specialist or recent discharge from hospital with changes to
med list?
Was the medication list reviewed and adjusted for: Prescribing cascade?
Was the medication list reviewed and adjusted for: Duplications?
Was the medication list reviewed and adjusted for: High-risk medications from Table
2?
Was the medication list reviewed and adjusted for: Matched medication with
diagnosis?
Was the medication list reviewed and adjusted for: Note any physiologic changes in
the patient?
Was the medication list reviewed and adjusted for: Decrease dose to lowest effective
dose?
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No

!
!
! !
!
!
! !
!
!
!
!
!
!
3. Did the Nurse Practitioners modify their prescribing habits with the older adults while using the
protocol?
Check Yes or No
Question
Did the nurse practitioners state in the survey that it helped with awareness of
the problem of polypharmacy?
Did the nurse practitioners state in the survey that it helped modify their
prescribing habits to avoid inappropriate prescribing in older adults?

89!

Yes

No

!
!
!
!
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Table 4. Table of Study Measures
Variable Name

!
!
!

!
!
!

Measure

!
!
!

Level of
measure

Time of
measurement

Ordinal

Survey, postimplementation
of protocol

Ordinal

Survey, postimplementation
of protocol

Ordinal

Survey, postimplementation
of protocol

Ordinal

Survey, postimplementation
of protocol

Ordinal

Survey, postimplementation
of protocol

Ratio

Survey, postimplementation
of protocol

Ordinal

Survey, postimplementation
of protocol
Survey, postimplementation
of protocol

OUTCOME VARIABLE (Nurse Practitioner Process Evaluation)
Does the protocol include enough
background information about the
problem of polypharmacy and
inappropriate prescribing?
Does the protocol allow the APRN
freedom to individualize the
protocol for each patient’s
medication list review?
Is the protocol feasible/appropriate
for and APRN in this practice
setting?

4-point Likert scale with
following choices: Not nearly
enough, Not quite enough, Just
right, More than enough.
4-point Likert scale with
following choices: Not nearly
enough, Not quite enough, Just
right, More than enough.
4-point Likert scale with
following choices: Not nearly
enough, Not quite enough, Just
right, More than enough.
Does the protocol provide the
4-point Likert scale with
minimum standard of care for the
following choices: Not nearly
clinical problem of polypharmacy? enough, Not quite enough, Just
right, More than enough.
Does the protocol provide the
4-point Likert scale with
minimum standard of care for
following choices: Not nearly
addressing inappropriate
enough, Not quite enough, Just
prescribing in the older adult
right, More than enough.
population?
How much time did it take to
Intervals of time: Less than 10
administer the protocol?
minutes, 10-15 minutes, 15-20
minutes, 20-25 minutes, 25-30
minutes
OUTCOME VARIABLE (Nurse Practitioner Satisfaction)
How would you rate the quality
of the Polypharmacy Protocol?
To what extent did the
Polypharmacy Protocol meet the
needs of your practice setting?

4-point Likert scale with
following choices: Poor, Fair,
Good, Excellent
4-point Likert scale with
following choices: None of my
needs have been met, Only a few
of my needs have been met, Most
of my needs have been met,
Almost all of my needs have been
met

90!

Ordinal

!
!
!
!
!
Did the Polypharmacy Protocol
help you address the problem of
polypharmacy and inappropriate
prescribing in your practice
setting?
Overall, how satisfied are you
with the Polypharmacy Protocol
in addressing polypharmacy and
inappropriate prescribing in your
practice setting?

!
!
!

!
!
!

!
!
!

4-point Likert scale with
following choices: Didn’t help,
Helped some, Helped a good bit,
Helped a great deal

Ordinal

Survey, postimplementation
of protocol

4-point Likert scale with
following choices: Very
dissatisfied, Dissatisfied, Mostly
satisfied, Very satisfied

Ordinal

Survey, postimplementation
of protocol
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DNP Practice Inquiry Project Conclusion
Polypharmacy is common among older adults and increases the risk of adverse

interactions that may interfere with cognition and cause other adverse events. To avoid this, the
protocol piloted for the DNP project in a primary care setting has been found to address
polypharmacy both simply and efficiently. The Polypharmacy Protocol screening instrument can
be used routinely to guide prescribing practice and reduce polypharmacy in older adult patients.
It also provides a strategy that can be incorporated into practice to reduce adverse drug reactions,
improve an older adult’s quality of life, and decrease unfavorable events such as falls,
hospitalizations, and changes in cognition.
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